Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Oral estramustine and cyclophosphamide in patients with metastatic hormonerefractory prostate carcinoma - A phase II study
Autore:
Bracarda, S; Tonato, M; Rosi, P; De Angelis, V; Mearini, E; Cesaroni, S; Fornetti, P; Porena, M;
Indirizzi:
Policlin Hosp, Div Med Oncol, I-06122 Perugia, Italy Policlin Hosp Perugia Italy I-06122 iv Med Oncol, I-06122 Perugia, Italy Policlin Hosp, Dept Urol, I-06122 Perugia, Italy Policlin Hosp Perugia Italy I-06122 p, Dept Urol, I-06122 Perugia, Italy
Titolo Testata:
CANCER
fascicolo: 6, volume: 88, anno: 2000,
pagine: 1438 - 1444
SICI:
0008-543X(20000315)88:6<1438:OEACIP>2.0.ZU;2-A
Fonte:
ISI
Lingua:
ENG
Soggetto:
PALLIATIVE END-POINTS; LOW-DOSE PREDNISONE; WITHDRAWAL SYNDROME; CLINICAL-TRIALS; CANCER; ANTIGEN; MANAGEMENT; CHEMOTHERAPY; ETOPOSIDE; MITOXANTRONE;
Keywords:
prostate carcinoma; hormone refractory; estramustine; cyclophosphamide;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
33
Recensione:
Indirizzi per estratti:
Indirizzo: Bracarda, S Policlin Hosp, Div Med Oncol, I-06122 Perugia, Italy Policlin Hosp Perugia Italy I-06122 , I-06122 Perugia, Italy
Citazione:
S. Bracarda et al., "Oral estramustine and cyclophosphamide in patients with metastatic hormonerefractory prostate carcinoma - A phase II study", CANCER, 88(6), 2000, pp. 1438-1444

Abstract

BACKGROUND. Nearly all cases of metastatic prostate carcinoma progress, after hormonal ablation, to a hormone refractory status. To the authors' knowledge no standard chemotherapy for patients with hormone refractory prostate carcinoma (HRPC) exists. In a prospective study, the efficacy and toxicity of an oral combination of estramustine and cyclophosphamide were evaluated. METHODS. Between March 1996 and April 1998, 32 consecutive patients (median age 74 years; range, 53-84 pears) with metastatic HRPC were treated with oral estramustine (10 mg/kg/day) and oral cyclophosphamide (2 mg/kg/day) for 14 days every 28 days. Inclusion criteria were previous complete androgenblockade, antiandrogen withdrawal evaluation, and clinical or biochemical disease progression. Response assessment was based on a decrease greater than or equal to 50% in the prostate specific antigen (PSA) level associated with improvement (or no worsening) in Eastern Cooperative Oncology Group (ECOG) performance status (PS) and relief of bone pain (if present). RESULTS. All patients were evaluable for efficacy and toxicity. PSA levelsdecreased by at least 50% in 14 patients (43.7%) (95% confidence interval,26.5-60.9), remained stable in 12 patients (37.5%), and rose in 6 patients(18.8%). ECOG PS was 0 in 5 of 14 patients, improved from 1 to 0 in 7 patients, and remained unchanged in 2 patients. Bone pain, present in 8 of 14 patients, disappeared in 7 and was partially relieved in 1. The median duration of response was 30 weeks (range, 8-88+ weeks). An objective partial response was obtained in two cases. Toxicity was mild and mainly gastrointestinal (World Health Organization [WHO] Grade 1). No cases of WHO Grade 3-4 hematologic toxicity occurred. CONCLUSIONS. The oral combination of estramustine and cyclophosphamide appears to be safe and effective in patients with HRPC. In responding patientsits use shows a clinical benefit in terms of improvement of ECOG PS and pain control. Cancer 2000;88:1438-44. (C) 2000 American Cancer Society.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 03/04/20 alle ore 07:20:16